Coronil and Swasari, first evidence based ayurvedic medicines to cure deadly coronavirus within a week

India: Patanjali Ayurved Limited, an ayurvedic healthcare products & consumer goods manufacturing company, launched COVID-19 medicines Coronil and Swasari. Patanjali collaborated with National Institute of Medical Sciences or NIMS University Jaipur and conducted clinical trials on around 280 coronavirus positive cases from cities such as Delhi, Ahmedabad, Meerut, among others. The company claims that within three days of drug administration 69% of the patients recovered and were tested negative for coronavirus and within 7 days, 100% of all the patients were cured and tested completely negative. The company also claims 100% recovery rate and 0% mortality rate. The medicine will be available at the Patanjali outlets across the country within a week and can be ordered online through e-commerce platform “Order Me”. The medicines are available in the form of kits which contains tablets Coronil and Swasari along with Anu Oil. Patanjali prescribes to take 2-2 tablets with hot water half an hour after the meal. The entire kit will cost around INR 545.

CEO of Patanjali stated that, “We appointed a team of scientists after COVID-19 outbreak. Firstly, the simulation was done, and compounds were identified which can fight the virus and stop its spread in the body. Then, we conducted a clinical case study on hundreds of positive patients, and we have got 100 per cent favorable results. After taking our medicine, COVID patients recovered in 3-14 days and then tested negative. So, we can say the cure for COVID is possible through Ayurveda. We are performing controlled clinical trials only. In the next 4-5 days, evidence and data will be released by us.”

According to TechSci Research, while the whole world is battling with the pandemic and scientists around the globe are working to find a medicine or vaccine or cure for the deadly virus, the launch of these ayurvedic medicines in India as potential coronavirus treatment with no fatality, side-effects and 100% recovery is expected to be a game changer. The medicines have been made in accordance with the Prime Minister’s “Make in India” approach. If the medicine becomes successful in treating the virus, India and the whole world will be able to eradicate coronavirus in no time. The success of these medicine will not only benefit the company but also benefit and strengthen the position of India as a whole across the globe.

However, much cannot be said as these claims have been made by the company. ICMR has distanced itself from all this, stating it does not deal with ayurvedic medicines. While, Ayush Ministry has asked the company to stop making any further claims and submit the clinical trials and drug composition related data to the company. The ministry has also asked the Uttarakhand Licensing Authority to provide copies of license and product approvals and has asked Patanjali to wait till the claims are duly corroborated.

According to a report published by TechSci Research, “India Ayurvedic Products Market By Category (Personal Care & Beauty and Healthcare), By Distribution Channel (Traditional Stores, Supermarkets/Hypermarkets, Online, and Others), By Region, By Company, Competition, Forecast & Opportunities, 2024”, the growth of ayurvedic products market in India can be attributed to rising awareness about healthy lifestyle & wellness and the awareness about various side effects of chemical medications. Moreover, strong marketing of different brands by major companies, in addition to huge endorsements by emerging spiritual leaders, are some major drivers for market of ayurvedic products in India.

According to another TechSci Research report, “Global Coronavirus Vaccine Market By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2, Others), By Vaccine Type (Inactivated Coronavirus Vaccine, Live Attenuated Coronavirus Vaccine, S-Protein Based Coronavirus Vaccine), By Product Type (Monovalent Vaccine v/s Multivariant Vaccine), By Route of Administration (Oral, Intramuscular, Subcutaneous), By Patient Type (Pediatric v/s Adult), By End User (Hospitals, Clinics, Research Institutes, Others), By Region, Forecast & Opportunities, 2025”, the global coronavirus vaccine market is expected to grow at a robust rate during the forecast period. The global coronavirus vaccine market is driven by the increasing prevalence of this disease across different parts of the globe. This has increased the need to protect the world from the virus, thereby expected to positively impact the market growth. Furthermore, increasing R&D activities by various pharmaceutical & biotechnology players for the development of potential vaccines is anticipated to foster the market growth. According to WHO, there are 70 coronavirus vaccines under development by different companies and organizations. Out of these, three vaccines are already being tested in human trials. The vaccine developed by the Hong Kong based biopharmaceutical firm CanSino Biologics Inc. and the Beijing Institute of Biotechnology is leading the race and is currently in the second phase of clinical trials. On the other hand, other vaccines developed by the US-based companies Moderna Inc. and Inovio Pharmaceuticals Inc., have also been put under human trials.